ストックスクリーナーアプリを入手
1.01
2.88%
-0.03
アフターアワーズ：
1.01
前日終値:
$1.04
開ける：
$1.03
24時間の取引高:
382.69K
Relative Volume:
0.59
時価総額：
$128.53M
収益：
-
当期純損益:
$-18.43M
株価収益率:
-6.4827
EPS:
-0.1558
ネットキャッシュフロー:
$-12.87M
1週間 パフォーマンス:
+11.53%
1か月 パフォーマンス:
-9.01%
6か月 パフォーマンス:
-25.19%
1年 パフォーマンス:
-51.21%
1日の値動き範囲:
$1.00
$1.08
1週間の範囲:
$0.8702
$1.11
52週間の値動き範囲:
$0.7615
$2.33
Tiziana Life Sciences Ltd Stock (TLSA) Company Profile
Compare TLSA vs VRTX, REGN, MRNA, ARGX, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
TLSA
Tiziana Life Sciences Ltd
|
1.01 | 128.53M | 0 | -18.43M | -12.87M | -0.1558 |
VRTX
Vertex Pharmaceuticals Inc
|
526.19 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
788.04 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
198.88 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
959.49 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
204.97 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Tiziana Life Sciences Ltd Stock (TLSA) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2020-12-22 | 開始されました | B. Riley Securities | Buy |
| 2018-12-17 | 開始されました | Laidlaw | Buy |
Tiziana Life Sciences Ltd (TLSA) 最新ニュース
TLSA Reiterated by BTIG -- Price Target Maintained at $7.00 - GuruFocus
BTIG Maintains Tiziana Life Sciences(TLSA.US) With Buy Rating, Maintains Target Price $7 - Moomoo
Small cap wrap: Tiziana Life Sciences, First Phosphate, Ocean Power Technologies, Midnight Sun Mining... - Proactive financial news
Tiziana Life Sciences completes patient visits in Phase 2a MS drug trial - Yahoo Finance
Tiziana Life Sciences to Announce Topline Data From Phase 2a Na-SPMS Trial in October - marketscreener.com
Tiziana Life Sciences (TLSA) Completes Phase 2a Trial, Faces Val - GuruFocus
Tiziana Life Sciences Completes Last Patient Visit in Phase 2a INFORM-MS Trial - TipRanks
Tiziana Life Sciences announces last patient completed Phase 2a INFORM-MS trial - TipRanks
Tiziana Life Sciences Announces Last Patient Last Visit in Phase 2a INFORM-MS Trial of Intranasal Foralumab in Non-Active Secondary Progressive Multiple Sclerosis - Quiver Quantitative
The last patient has finished an MS drug trial. Early results are expected in October. - Stock Titan
Last patient finishes Tiziana (TLSA) MS trial ahead of October data - Stock Titan
Tiziana Life Sciences Ltd(NasdaqCM: TLSA) dropped from S&P Global BMI Index - marketscreener.com
Tiziana Life Sciences stock jumps on MS trial partnership - Investing.com
Tiziana (TLSA) Up +25.96% — Will the Rally Hold Through Earnings? 2026-09-17Combination Correction - siam.in
Why Is Tiziana Life Sciences Stock Gaining Thursday? - Benzinga
Tiziana Life Sciences (NASDAQ: TLSA) Enters MOU to Launch RRMS Combination Therapy Trial - kalkinemedia.com
Small cap wrap: Sigma Lithium, Tiziana Life Sciences, Gunnison Copper, Purepoint Uranium... - Proactive financial news
Tiziana Life Sciences partners with Saudi institutions on MS combination therapy trial - Yahoo Finance
Tiziana Life Sciences stock jumps on MS trial partnership By Investing.com - Investing.com Canada
Tiziana Life Sciences Signs Saudi Collaboration MOU for New Multiple Sclerosis Trial - TipRanks
Tiziana Life Sciences (TLSA) Advances MS Clinical Trial Collaboration Amid Challenging Valuation - GuruFocus
Tiziana Life Sciences signs MOU with KAIMRC in Saudi Arabia - TipRanks
Tiziana Life Sciences Signs MOU with KAIMRC and Foundation for Neurologic Diseases to Study Intranasal Foralumab in RRMS - Quiver Quantitative
Tiziana (TLSA) lines up MS trial for patients failing current drugs with a nasal antibody twist. - Stock Titan
Tiziana Life Sciences Announces Signing of Mo - Moomoo
A planned MS trial will test Tiziana’s nasal drug with existing treatment - Stock Titan
TLSA: Tiziana Life Sciences Ltd Latest Stock Price, Analysis, News and Trading Ideas - Stocktwits
BTIG Initiates Tiziana Life Sciences(TLSA.US) With Buy Rating, Announces Target Price $7 - Moomoo
Tiziana Life Sciences gets Buy rating from BTIG on Treg-based approach to neurodegeneration - Yahoo Finance
Small cap wrap: Tiziana Life Sciences, Thistle Resources, Alvopetro, BioHarvest... - Proactive financial news
Tiziana Life Sciences initiated with a Buy at BTIG - TipRanks
This Occidental Petroleum Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday - Benzinga
TLSA Initiated Coverage by BTIG -- Price Target Set at $7.00 - GuruFocus
BTIG Initiates Tiziana Life Sciences at Buy With $7 Price Target - marketscreener.com
BTIG initiates Tiziana Life Sciences stock with buy on MS drug - Investing.com India
Wall Street ends on a mixed note as Dow gains despite semiconductor slump - proactiveinvestors.com.au
Market movers: Strategy, Bitmine, Tiziana Life Sciences... - Proactive Investors
Tiziana (NASDAQ: TLSA) highlights intranasal ALS trial and MS data - Stock Titan
Tiziana Life Sciences Announces Poster Presentation on Phase 2a BANYAN Clinical Trial of Intranasal Foralumab at ALS Nexus 2026 - NTB Kommunikasjon
Tiziana Life Sciences Ltd (TLSA) Earnings Forecast: Future EPS & Revenue Growth Estimates - tradingkey.com
Tiziana Life Sciences (TLSA) insider adds 42,357 shares via Panetta Partners - Stock Titan
Tiziana Life Sciences Ltd (TLSA) director adds 15,000 shares in open-market buy - Stock Titan
Tiziana Life Sciences CEO & Executive Director Acquires 18% More Stock - simplywall.st
Tiziana Life Sciences (TLSA) CEO Boosts Stake Amid Unprofitable Operations and Low Valuation - GuruFocus
TLSA | Tiziana Life Sciences Ltd. Insider Trading - Quiver Quantitative
Insider Buying: Tiziana Life Sciences (NASDAQ:TLSA) CEO Purchases 83,807 Shares of Stock - marketbeat.com
Ivor Elrifi Acquires 237,616 Shares of Tiziana Life Sciences (NASDAQ:TLSA) Stock - marketbeat.com
Tiziana Life Sciences : Announces Purchase of Shares by Chief Executive Officer - marketscreener.com
Tiziana Life Sciences (Nasdaq: TLSA) CEO boosts stake with 321,423-share buy - Stock Titan
Tiziana Life Sciences announces CEO share purchase - Proactive financial news
Tiziana Life Sciences Announces Purchase of Shares by Chief Executive Officer - The Manila Times
Tiziana Life Sciences Ltd (TLSA) 財務データ
収益
当期純利益
現金流量
EPS
3.06%
2.55%
大文字化:
|
ボリューム (24 時間):